‘Nesina Act’ that improved the fundamental cause of diabetes is expected to shake the market
The first complex of alogliptin and a TZD type composite, ‘Nesina Act’, has attracted attention.
Takeda Pharmaceuticals Korea unveiled at the press conference on 11th that the new drug ‘Nesina Act’, having the DDP-4 inhibitor ‘Nesina (generic name: alogliptin)’ and the thiazolidinedione (TZD) ty...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
